Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137173 · ClinicalTrials.gov registry record · Phase 3
Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
A Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 3
- Development phase
- 679
- Enrollment target
- 20
- Study locations
NCT03137173: Completed Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, sponsored by Basilea Pharmaceutica.
NCT03137173 is a Phase 3 study of Acute Bacterial Skin and Skin Structure Infections that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 679 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03137173, a Phase 3 study of Acute Bacterial Skin and Skin Structure Infections, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 679 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Primary Outcome
Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), survival for ≥ 72 hours and no rescue therapy in the ITT population
Conditions Studied
Interventions
- DRUG ceftobiprole medocaril
- DRUG vancomycin+aztreonam
Study Locations (20)
California
- Physician Alliance Research Center - Anaheim
- Saint Joseph's Clinical Research - Anaheim
- eStudySite - Chula Vista - PPDS - Chula Vista
- Central Valley Research LLC - Fresno
- Marvel Clinical Research - Huntington Beach
- eStudySite - La Mesa - PPDS - La Mesa
- Omnibus Clinical Research - La Palma
- Alliance Research LLC - Long Beach
- Long Beach Clinical Trials - Long Beach
- Central Valley Research, LLC - Modesto
Other
- University Multiprofile Hospital for Active Treatment - Pleven
- University Multiprofile Hospital for Active Treatment - Plovdiv
- University Multiprofile Hospital for Active Treatment - Rousse
- "University Multiprofile Hospital for Active Treatment and Emergency Medicine ""N. I. Pirogov"", Clinic of Purulent-Septic Surgery-"N.I. Pirogov"" - Sofia
Florida
- Gonzalez MD and Aswad MD Health Services - Coral Gables
- L&C Professional Medical Research Institute - Miami
Nevada
- eStudySite - Las Vegas - PPDS - Las Vegas
- Excel Clinical Research - Las Vegas
Montana
- Mercury Street Medical Group - Butte
New Jersey
- South Jersey Infectious Disease - Somers Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2019-04-22 |
| Phase | Phase 3 |
What the finished NCT03137173 record still lists
NCT03137173 is an interventional study that assigns participants to a tested intervention. The registered 679 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Acute Bacterial Skin and Skin Structure Infections appearing as the primary indexed condition, and to 2 interventions - of which ceftobiprole medocaril is the first listed.
NCT03137173 names 20 study sites across 6 states, led by California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT03137173 about?
NCT03137173 is a clinical study titled "Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections". This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSS...
What is the current status of trial NCT03137173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 679 participants. The study started on 2018-02-19. Estimated completion is 2019-04-22.
What conditions does trial NCT03137173 study?
This clinical trial studies the following conditions: Acute Bacterial Skin and Skin Structure Infections.
What interventions are being tested in trial NCT03137173?
The interventions under investigation include: ceftobiprole medocaril (DRUG), vancomycin+aztreonam (DRUG).
Who is sponsoring clinical trial NCT03137173?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03137173 being conducted?
This trial has 20 study locations across California, Florida, Montana, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Bacterial Skin and Skin Structure Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03137173's enrollment target sits among peer trials
679 536th of 2000 higher than 1,465 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI